Didier Betbeder
CSO Vaxinano, France Email: Didier.betbeder@vaxinano.com
VALIDATE Role: Network Investigator
Research Keywords: Leishmaniasis, Nasal vaccine, Nanoparticles
Biography: Pr. Didier BETBEDER has 30 years’ experience in drug delivery using colloids, ranging from basic research to clinical studies. In the 1990s as director R&D in Nanomedicine he was the pioneer of the nasal administration of vaccines using nanoparticles from preclinical research to clinical trials. Working with the World Health Organisation, he obtained his PhD in 1988 on a treatment for sleeping sickness, before spending 2 years as a post-doctoral fellow at the University of Warwick (England). He was then engaged by BioEurope, a company specializing in biocatalysis, before joining Biovector Therapeutics (France) as Research director from 1992 – 2001. Nasal vaccine formulations using polysaccharide nanoparticles have been clinically trialled with BioChem Pharma (Canada), SmithKline Beecham (Belgium) and Novartis (Chiron, Italy), and he has collaborated with RIBI Immunochem (US), Merck and Sanofi Pasteur. He then entered academia, becoming full Professor at the Universities of Artois and Lille. He founded Vaxinano in 2016 and became president and CSO in September 2019. To harness his research, he founded VAXINANO in 2016, and the company is developing vaccines for human and animal health. In a world premiere, Vaxinano developed a vaccine and has conducted extensive research on the use of this technology for a large number of other vaccines to prevent or treat parasitic, viral (influenza and covid) and bacterial infections. Vaxinano technology allows the development of nasal vaccines as the nanoparticles used allow the vaccine to cross the mucus and deliver cleverly the antigens to the immune cells without the addition of adjuvants. He joined the company as full time CEO & CSO in September 2019. He has extensive experience in Nanomedicine, and in particular on prophylactic and therapeutic vaccines. He was president of the (GTRV) from 2004-08, board member of SFNano (French Society of Nanomedicine) and has over 130 international publications and 25 patents to his name.
Related Websites:
|
